Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
AIDS
COVID‐19 vaccine
SARS‐CoV‐2 variants
XBB‐sublineages
neutralizing response
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
18
03
2024
received:
04
01
2024
accepted:
01
04
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
ppublish
Résumé
We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/mm
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29598Subventions
Organisme : Ministero della Salute
Organisme : Valentino spa
Informations de copyright
© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised. Update March, 8 2024. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
WHO. Statement on the antigen composition of COVID‐19 vaccines. https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
Chalkias S, McGhee N, Whatley JL, et al. Safety and immunogenicity of XBB.1.5‐Containing mRNA vaccines. medRxiv. 2023;2023:08.22.23293434. doi:10.1101/2023.08.22.23293434
Rubin R. This fall's COVID‐19 vaccines will target omicron XBB subvariants, but who needs them remains to be seen. JAMA. 2023;330(4):299. doi:10.1001/jama.2023.10053
ECDC. SARS‐CoV‐2 variants of concern as of 15 December 2023. Published 2023. https://www.ecdc.europa.eu/en/covid-19/variants-concern
European Respiratory Virus, Surveillance. Overview of respiratory virus epidemiology in the EU/EEA Weekly overview (Week 49, 2023 Published 2023. erviss.org).
CDC. COVID Data Tracker. Published 2023. https://covid.cdc.gov/covid-data-tracker/#variant-summary
Istituto Superiore di Sanità. Monitoraggio varianti indagini rapide Novembre 2023. Published 2023. https://www.epicentro.iss.it/coronavirus/pdf/sars-cov-2-monitoraggio-varianti-indagini-rapide-novembre-2023.pdf
Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid‐19 milestone attained—a correlate of protection for vaccines. N Engl J Med. 2022;387(24):2203‐2206. doi:10.1056/NEJMp2211314
Menegale F, Manica M, Zardini A, et al. Evaluation of waning of SARS‐CoV‐2 vaccine–induced immunity. JAMA Netw Open. 2023;6(5):e2310650. doi:10.1001/jamanetworkopen.2023.10650
Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid‐19 among adults in the US from the VISION network: test negative, case‐control study. BMJ. 2022;3:e072141. doi:10.1136/bmj-2022-072141
Qu P, Faraone JN, Evans JP, et al. Durability of booster mRNA vaccine against SARS‐CoV‐2 BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(14):1329‐1331. doi:10.1056/NEJMc2210546
Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS‐CoV‐2 omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nature Med. 2023;29(2):344‐347. doi:10.1038/s41591-022-02162-x
Cohen J. Should I get a COVID‐19 booster? Science. 2023. doi:10.1126/science.adk7661
Ministero della Salute. CIRCOLARE del Ministero della Salute n. 30088. 2023.
Vergori A, Matusali G, Lepri AC, et al. Neutralizing activity and T‐cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV. Int J Infect Dis. 2023;134:195‐199. doi:10.1016/j.ijid.2023.06.010
Meschi S, Colavita F, Bordi L, et al. Performance evaluation of Abbott ARCHITECT SARS‐CoV‐2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test. J Clin Virol. 2020;129:104539. doi:10.1016/j.jcv.2020.104539
Vergori A, Cozzi Lepri A, Cicalini S, et al. Immunogenicity to COVID‐19 mRNA vaccine third dose in people living with HIV. Nat Commun. 2022;13(1):4922. doi:10.1038/s41467-022-32263-7
Ehmsen S, Pedersen RM, Bang LL, et al. BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID‐19 booster in patients with cancer. Cancer Cell. 2023;41(4):649‐650. doi:10.1016/j.ccell.2023.02.003
Wang W, Goguet E, Paz S, et al. Bivalent coronavirus disease 2019 vaccine antibody responses to omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens. J Infect Dis. 2023;228(4):439‐443. doi:10.1093/infdis/jiad111
Hoffmann M, Behrens GMN, Arora P, et al. Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation. Lancet Infect Dis. 2023;23(1):25‐28. doi:10.1016/S1473-3099(22)00792-7
Lasrado N, Collier A‐RY, Miller J, et al. Waning immunity against XBB.1.5 following bivalent mRNA boosters. bioRxiv Prepr Serv Biol. 2023. doi:10.1101/2023.01.22.525079
Amano M, Otsu S, Uemura Y, et al. Neutralization against omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2‐vaccinated HCWs with or without risk factors, or following BT infection with omicron. Sci Rep. 2023;13(1):17404. doi:10.1038/s41598-023-44484-x
Gravenstein S, DeVone F, Oyebanji OA, et al. Durability of immunity and clinical protection in nursing home residents following bivalent SARS‐CoV‐2 vaccination. medRxiv. 2023:2023.04.25.23289050. doi:10.1101/2023.04.25.23289050
Cheung PK, Lapointe HR, Sang Y, et al. SARS‐CoV‐2 live virus neutralization after four COVID‐19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. AIDS. 2023;37(5):F11‐F18. doi:10.1097/QAD.0000000000003519
The Lancet Infectious Diseases. Why hybrid immunity is so triggering. Lancet Infect Dis. 2022;22(12):1649. doi:10.1016/S1473-3099(22)00746-0
Zhang L, Kempf A, Nehlmeier I, et al. Neutralisation sensitivity of SARS‐CoV‐2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis. 2023;23(10):e391‐e392. doi:10.1016/S1473-3099(23)00547-9
Tarke A, Coelho CH, Zhang Z, et al. SARS‐CoV‐2 vaccination induces immunological T cell memory able to cross‐recognize variants from Alpha to Omicron. Cell. 2022;185(5):847‐859.e11. doi:10.1016/j.cell.2022.01.015
Geers D, Shamier MC, Bogers S, et al. SARS‐CoV‐2 variants of concern partially escape humoral but not T cell responses in COVID‐19 convalescent donors and vaccine recipients. Sci Immunol. 2021;6(59):abj1750. doi:10.1126/sciimmunol.abj1750
Tseng HF, Ackerson BK, Sy LS, et al. mRNA‐1273 bivalent (original and Omicron) COVID‐19 vaccine effectiveness against COVID‐19 outcomes in the United States. Nat Commun. 2023;14(1):5851. doi:10.1038/s41467-023-41537-7
Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID‐19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23(8):914‐921. doi:10.1016/S1473-3099(23)00122-6
Link‐Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID‐19–associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579‐588. doi:10.15585/mmwr.mm7221a3
Fabiani M, Mateo‐Urdiales A, Sacco C, et al. Italian Integrated Surveillance of COVID‐19 study group and of the Italian COVID‐19 Vaccines Registry group Protection against severe COVID‐19 after second booster dose of adapted bivalent (original/Omicron BA.4‐5) mRNA vaccine in persons ≥60 years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill. 2023;28(8):2300105. doi:10.2807/1560-7917.ES.2023.28.8.2300105
Modjarrad K. Monovalent XBB.1.5 BNT162b2 COVID‐19 vaccine. In: Meeting of the advisory committee on immunization practices (ACIP). 2023:1‐14. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/10-COVID-Modjarrad-508.pdf